EU Medicines Agency Panel Backs Orphelia Pharma's Kizfizo for Glioblastoma Multiforme, Malignant Glioma

MT Newswires · 2d ago
08:02 AM EDT, 10/16/2026 (MT Newswires) -- The European Medicines Agency's human medicines committee recommended approval of France-based Orphelia Pharma's Kizfizo for newly diagnosed glioblastoma multiforme in adults and recurrent or progressing malignant glioma in adults and children aged one and older. The recommendation is backed by satisfactory results in studies and its bioequivalence to Merck & Co.'s (6MK.F) Temodal, according to a Friday note. The drug remains subject to final approval from the European Commission.